Title |
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials
|
---|---|
Published in |
Investigational New Drugs, February 2019
|
DOI | 10.1007/s10637-019-00736-0 |
Pubmed ID | |
Authors |
Dylan J. Martini, Yuan Liu, Julie M. Shabto, Colleen Lewis, Meredith R. Kline, Hannah Collins, Mehmet Akce, Haydn T. Kissick, Bradley C. Carthon, Walid L. Shaib, Olatunji B. Alese, Rathi N. Pillai, Conor E. Steuer, Christina S. Wu, David H. Lawson, Ragini R. Kudchadkar, Viraj A. Master, Bassel F. El-Rayes, Suresh S. Ramalingam, Taofeek K. Owonikoko, R. Donald Harvey, Mehmet Asim Bilen |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 8 | 80% |
Brazil | 1 | 10% |
Japan | 1 | 10% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 60% |
Scientists | 3 | 30% |
Practitioners (doctors, other healthcare professionals) | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 43 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 14% |
Researcher | 6 | 14% |
Student > Doctoral Student | 3 | 7% |
Lecturer | 3 | 7% |
Professor > Associate Professor | 3 | 7% |
Other | 5 | 12% |
Unknown | 17 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 37% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Agricultural and Biological Sciences | 1 | 2% |
Nursing and Health Professions | 1 | 2% |
Other | 2 | 5% |
Unknown | 20 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2019.
All research outputs
#5,544,187
of 23,128,387 outputs
Outputs from Investigational New Drugs
#246
of 1,177 outputs
Outputs of similar age
#114,163
of 437,541 outputs
Outputs of similar age from Investigational New Drugs
#3
of 19 outputs
Altmetric has tracked 23,128,387 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,177 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,541 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.